Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's abiraterone improves survival in first Phase III prostate cancer trial

This article was originally published in Scrip

Executive Summary

Johnson & Johnson's billion dollar acquisition of Cougar Biotechnology last year to gain access to a novel, hormonal anticancer, looks like it may be paying off; abiraterone acetate - which works in a different way to standard hormonal therapies in prostate cancer - improved overall survival in its first Phase III trial in men with advanced/metastatic prostate cancer who had progressed on previous hormonal therapy and chemotherapy.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC010127

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel